Ash 2021 – Forma takes on a second Agios drug
Now in Servier’s hands, the Agios-discovered Tibsovo could soon face competition from Forma’s olutasidenib.
Daiichi could be rewarded for persisting with Vanflyta
A front-line trial yields a positive result two years after the drug got a US complete response letter.
Global pharma stocks struggle in the third quarter
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
Esmo 2021 movers – a handful of biotech winners emerge
Leap and Innate were clear winners on the stock market during the medical meeting, while Astrazeneca’s strong performance stands out among the large caps.
Vantage Esmo 2021 roundup
Here's a roundup of Vantage's coverage of the 2021 European Society for Medical Oncology congress.
The heat is on Gilead as Tropics readout nears
Trodelvy has a chance to score in a study designed to expand its use, but given Gilead’s R&D track record nothing is certain.
Esmo 2021 – Astra lays out a grand vision for Enhertu
But proving that the drug’s toxicities are manageable in the real world will become more important as it moves into earlier treatment settings.
Esmo 2021 – Enhertu sets a very high bar
A move into the larger second-line breast cancer setting is surely on the way for the Astrazeneca and Daiichi drug.
